Abstract
BACKGROUND/AIM: Fibroblast Growth Factor Receptor (FGFR) gene fusions are recognized as pivotal oncogenic drivers, contributing to cancer initiation and progression across diverse malignancies. These fusions often represent significant therapeutic targets, particularly in challenging malignancies like cholangiocarcinoma. This study aimed to characterize the novel FGFR2::SHTN1 fusion, identify it as a de novo chimeric protein, and elucidate its precise oncogenic mechanism. MATERIALS AND METHODS: FGFR2::SHTN1 fusions were identified via cancer genomics databases and modeled using AlphaFold and HADDOCK. SHTN1 variants were expressed in Neuro-2a cells for coimmunoprecipitation, purification, and native polyacrylamide gel electrophoresis to assess oligomerization. Structural modeling included membrane embedding with Chemistry at HARvard Macromolecular Mechanics-Graphical User Interface (CHARMM-GUI). RESULTS: We found that FGFR2::SHTN1 is an in-frame fusion formed by the joining of upstream FGFR2 exons 1-17 with downstream SHTN1 exons 7-17 in human, resulting in a chimeric protein retaining the intact FGFR2 tyrosine kinase domain. Our analyses revealed that Shootin1 inherently forms oligomers through its coiled-coil domains, which, within the fusion, mediate ligand-independent dimerization and constitutive activation of FGFR2. CONCLUSION: Our findings establish FGFR2::SHTN1 as a potent oncogenic driver in various cancers, particularly in cholangiocarcinoma, highlighting a unique mechanism of constitutive activation mediated by Shootin1's CCD-II domain. This study represents the first molecular characterization of the FGFR2::SHTN1 fusion, advances understanding of FGFR2 fusion biology, and identifies a particular target for future diagnostic and therapeutic strategies in relevant malignancies.